QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.


Using AI technology, IPA Interpret helps distill complex differential expression analyzes into actionable insights, allowing researchers to understand which genes are involved in a disease, a biological process, or a response to a drug or environmental condition.


IPA, which forms the basis of IPA Interpret, has more than 50,000 citations and a high-quality, manually curated knowledge base. This widely recognized platform structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs, chemicals and other objects. With IPA’s curated knowledge base, scientists can confidently predict and validate new target-disease and drug-disease relationships.


Combining this extensive knowledge with advanced analytics and AI algorithms, IPA Interpret now automatically analyzes, compares and contextualizes complex gene expression datasets available in IPA, identifying key biological processes, pathways and networks in a streamlined web page report.


“IPA Interpret is a breakthrough in molecular data analysis, combining the best of human expertise and AI technology,” said Dominic John, Vice President of QIAGEN Digital Insights. “Our enhanced approach, leveraging AI and natural language processing with humans, ensures our customers have reliable, high-quality data with the causal relationships needed to drive AI insights. IPA Interpret embodies this approach and enables more researchers to discover deeper insights and make informed decisions faster.”


One of the standout features of IPA Interpret is the ability to generate comprehensive reports that can be easily shared with colleagues and collaboration partners. With a simple link, researchers can disseminate their findings, promoting collaboration and accelerating the spread of scientific knowledge. Additionally, IPA Interpret provides updated graphical representations of key results, increasing the clarity and impact of the insights.


QIAGEN is continuously integrating AI technology into its QDI portfolio. In early 2024, QIAGEN released an AI-driven biomedical knowledge base to drive data-driven drug discovery and in late 2023, QIAGEN released an AI-driven enhancement to its market-leading QIAGEN Clinical Insight Interpret product capabilities.


IPA Interpret is an integrated part of QIAGEN Ingenuity Pathway Analysis and is available to active licensed subscribers. For more information please visit:




About QIAGEN Digital Insights


QIAGEN Digital Insights (QDI), the bioinformatics company of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and physicians. QDI has more than 25 years of industry experience, 90,000 users worldwide, more than 100,000 citations in scientific articles, more than 3 million profiled patient cases and more than 40 billion scientific data points. The portfolio includes expertly curated genomic and clinical knowledge solutions, as well as bioinformatics software and services for efficient data management, sharing and actionable insights. More information at




About QIAGEN


QIAGEN NV, a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions connect these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in molecular diagnostics (human healthcare) and life sciences (academic, pharmaceutical R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,900 people in more than 35 locations worldwide. More information can be found at




Forward-looking statement




Certain statements in this press release may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relate to QIAGEN’s products, the timing for launch and development, marketing and/or regulatory approvals, financial and operating prospects, growth and expansion, partnerships, markets, strategy or results of operations, including but not limited to the expected adjusted net sales and adjusted diluted earnings results are forward-looking; such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of business results and allocations between customer categories, commercial development of markets for our products to customers in academia, pharmaceuticals, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and in manufacturing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; government actions, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and their impact on demand for our products and other aspects of our business, or other acts of God; as well as the possibility that anticipated benefits related to recent or upcoming acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For more information, please refer to discussions in reports QIAGEN has filed or furnished to the U.S. Securities and Exchange Commission.


Source: QIAGEN NV


Category: Business





Sitemap of qkyasmpjvw.csgobum.ru

Cannabis News RSS Feeds: Weedrss.com

1000+ unique media and news posts every 24 hours…

Published 2 hours ago
Published 7 hours ago
Published 13 hours ago
Published 16 hours ago
Published 17 hours ago
Published 17 hours ago
Published 20 hours ago
Published 21 hours ago
Published 21 hours ago
Published 21 hours ago
Published 22 hours ago